The Osteoblast-Adhesive Peptide from Bachem Holding AG - tiny KRSR sequence, big role in bone research
29.06.2026 - 04:49:22 | ad-hoc-news.de
Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-29, 04:48. Details in the imprint.
The Osteoblast-Adhesive Peptide from Bachem Holding AG sits in a small vial, clear solution glinting under the lab light as a pipette tip breaks the surface tension. One drop goes onto a culture plate, and bone cells start to tell researchers how well they can hold on.
What this peptide actually is
At its core, the Osteoblast-Adhesive Peptide is the short amino-acid sequence H-Lys-Arg-Ser-Arg-OH, often abbreviated as KRSR, supplied here as a 25 mg research-grade reagent. It is designed to selectively enhance heparan sulfate-mediated osteoblast adhesion mechanisms on treated surfaces.
Bachem positions the peptide squarely for bone-cell and tissue-engineering research, as well as for the design of dental and orthopedic biomaterials where controlling how osteoblasts attach can be decisive. The sequence itself is covered by U.S. Patent No. 6,262,017 B1, owned by Rensselaer Polytechnic Institute.
How it is used in the lab
Walk into a biomaterials lab and you will typically see the Osteoblast-Adhesive Peptide used to coat scaffolds, slides, or microplate wells before osteoblasts are seeded. Researchers then quantify how many cells adhere, how they spread, and whether they form a more consistent layer.
Because Bachem supplies the peptide as a defined 25 mg quantity with a clear catalog reference, labs can standardize protocols and dilution series. The vial feels almost weightless in the hand, yet its contents set the tone for how a whole experimental series behaves over several days.
Background on Bachem Holding AG shares
From niche research reagents like the Osteoblast-Adhesive Peptide to large-scale peptide APIs, Bachem’s portfolio matters for long-term holders of Bachem Holding AG shares.
Why patent and licensing matter
One detail that often surprises young researchers is the licensing clause attached to this peptide. Purchasers of up to 5 grams per year are authorized by Rensselaer Polytechnic Institute to use it for research purposes without seeking a separate agreement, as long as they stay within that volume.
Beyond that threshold, buyers must secure a written license from RPI, which adds an extra layer of planning for industrial users. In practice, that pushes the peptide firmly into the research-reagent bracket and makes it less suitable for high-volume commercial coating processes.
How Bachem fits into peptide supply
Bachem, led by CEO Thomas Meier, has built its reputation over decades as a specialist in peptide synthesis for both research and pharmaceutical applications. The Osteoblast-Adhesive Peptide sits on the research side of this portfolio, alongside hundreds of catalog peptides.
For lab managers, the value is less in marketing claims and more in consistent batch-to-batch quality and documentation. When experiments hinge on subtle differences in adhesion, a reliable supplier can save weeks of troubleshooting and repeated cell culture runs.
Where the product shines
The KRSR sequence is attractive because it focuses on osteoblasts specifically, allowing biomaterials teams to distinguish bone-forming cells from other cell types during adhesion tests. That specificity makes it easier to tune scaffold surfaces for better integration with bone tissue.
In dental and orthopedic research, coating prototypes with this peptide can yield cleaner, more interpretable adhesion data. Plates look tidier under the microscope, with osteoblasts forming a more continuous layer instead of patchy islands that complicate analysis.
Limitations and practical considerations
The flip side is that the peptide is a research tool, not a certified clinical coating. It is not meant to go directly into implants destined for patients, and any translation into medical products requires separate validation and regulatory pathways.
Its 25 mg pack size, while practical for most labs, demands careful handling and storage. If a researcher leaves the vial open too long or miscalculates the coating concentration, an entire batch of experiments can end with sobering, inconclusive adhesion curves.
Stock context for Bachem
Overall, the Osteoblast-Adhesive Peptide is a small but telling example of how Bachem continues to serve highly specialized research niches alongside its larger pharmaceutical contracts. Bachem Holding AG shares (ISIN CH0012530207) trade on SIX Swiss Exchange, giving investors exposure to this broader peptide ecosystem.
Key data on the Osteoblast-Adhesive Peptide
- Product: Osteoblast-Adhesive Peptide H-Lys-Arg-Ser-Arg-OH (KRSR)
- Manufacturer: Bachem Holding AG
- Category: Classic research peptide reagent
- Launch: Available for research use for several years, used in bone and biomaterials studies
- RRP / Price: Supplied as a 25 mg vial, pricing typically aligned with specialist peptide reagents in the research segment
- Availability: Distributed via Bachem and international lab-supply channels, commonly ordered in Europe and North America
- Target group: Academic and industry researchers in bone-cell biology, tissue engineering, dental and orthopedic biomaterials
- Highlight / USP: Short KRSR sequence tailored to osteoblast adhesion via heparan sulfate-mediated mechanisms, under a defined patent and licensing framework
This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.
